Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Risk management programs and reimportation

Executive Summary

FDA shares concerns about the potential for reimportation to circumvent the distribution program set up for RU-486, McClellan says, but concern extends to all drugs covered by risk management programs. "This is a general concern about the safety of drugs that are imported that we don't regulate." During House debate on reimportation, PhRMA suggested to pro-life groups that they may have a stake in the vote based on the potential that the bill would ease access to RU-486 (1"The Pink Sheet" July 28, 2003, p. 13)...
Advertisement

Related Content

Rx Reimportation Passes House; CBO Score May Keep It Out Of Medicare Rx
Rx Reimportation Passes House; CBO Score May Keep It Out Of Medicare Rx
Advertisement
UsernamePublicRestriction

Register

PS042297

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel